Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018 / 임상당뇨병
Journal of Korean Diabetes
;
: 71-75, 2018.
Article
in Korean
| WPRIM
| ID: wpr-726887
ABSTRACT
The management of type 2 diabetes mellitus should comprise healthy lifestyle modifications along with tailored pharmacologic treatment. Traditionally, the American Diabetes Association (ADA)'s Diabetes Management Guidelines have not prioritized specific anti-diabetic drugs over others with regard to cardiovascular disease (CVD) and mortality prevention. Recently, two novel anti-diabetic medications proved to be significantly protective against future CVD and mortality, regardless of the glycemic levels achieved in type 2 diabetic patients with pre-existing CVD. The 2018 ADA Guidelines recommend SGLT2 inhibitor and/or GLP-1 receptor agonist be used for type 2 diabetes patients with atherosclerotic CVD after metformin monotherapy failure. Considering the value of CVD protection in the management of diabetes mellitus, this minor guideline adjustment could have far-reaching implications.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Cardiovascular Diseases
/
Mortality
/
Diabetes Mellitus
/
Diabetes Mellitus, Type 2
/
Sodium-Glucose Transporter 2
/
Glucagon-Like Peptide-1 Receptor
/
Life Style
/
Metformin
Type of study:
Practice guideline
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of Korean Diabetes
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS